Subtle changes in neurotransmission that occur during Alzheimer’s disease have been tough to track in living people. A new positron emission tomography tracer may change that. In the January 12 ...
The FDA approved UCB SA's UCBJF UCBJY Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback